{"id":21077,"date":"2025-08-24T23:26:08","date_gmt":"2025-08-24T23:26:08","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/21077\/"},"modified":"2025-08-24T23:26:08","modified_gmt":"2025-08-24T23:26:08","slug":"hcplive-5-stories-in-under-5-week-of-08-17","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/21077\/","title":{"rendered":"HCPLive 5 Stories in Under 5: Week of 08\/17"},"content":{"rendered":"<p class=\"pb-2\">Welcome to HCPLive&#8217;s 5 Stories in Under 5\u2014your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let\u2019s dive into the latest updates impacting clinicians and healthcare providers like you!<\/p>\n<p>Interested in a more traditional, text rundown? <a target=\"_self\" href=\"http:\/\/hcplive.com\/view\/the-hcpfive-top-news-for-healthcare-providers-from-the-week-of-08-17\" rel=\"nofollow noopener\">Check out the HCPFive<\/a>!<\/p>\n<p><strong>Top 5 Healthcare Headlines for August 17-23, 2025:<\/strong><br \/>1. <a target=\"_blank\" href=\"https:\/\/www.hcplive.com\/view\/fda-approves-donidalorsen-to-prevent-hereditary-angioedema-attacks\" rel=\"nofollow noopener\"><strong>FDA Approves Donidalorsen to Prevent Hereditary Angioedema Attacks<\/strong><\/a><\/p>\n<p class=\"pb-2\">The FDA approved donidalorsen (DAWNZERA) for preventing HAE attacks in patients 12 years and older, supported by phase 3 OASIS trial data.<\/p>\n<p class=\"pb-2\">2. <a target=\"_blank\" href=\"https:\/\/www.hcplive.com\/view\/fda-grants-atumelnant-orphan-drug-designation-for-congenital-adrenal-hyperplasia\" rel=\"nofollow noopener\"><strong>FDA Grants Atumelnant Orphan Drug Designation for Congenital Adrenal Hyperplasia<\/strong><\/a><\/p>\n<p class=\"pb-2\">Atumelnant received FDA Orphan Drug Designation after phase 2 results showed rapid, sustained reductions in key biomarkers for congenital adrenal hyperplasia.<\/p>\n<p class=\"pb-2\">3. <a target=\"_blank\" href=\"https:\/\/www.hcplive.com\/view\/semaglutide-reduces-medical-costs-healthcare-resource-utilization-in-heart-failure\" rel=\"nofollow noopener\"><strong>Semaglutide Reduces Medical Costs, Healthcare Resource Utilization in Heart Failure<\/strong><\/a><\/p>\n<p class=\"pb-2\">A real-world analysis found semaglutide 2.4 mg reduced all-cause medical costs by 28% and inpatient hospitalization costs by 55% in patients with obesity and heart failure.<\/p>\n<p class=\"pb-2\">4. <a target=\"_blank\" href=\"https:\/\/www.hcplive.com\/view\/re104-reduces-postpartum-depression-symptoms-by-day-7-in-phase-2-reconnect\" rel=\"nofollow noopener\"><strong>RE104 Reduces Postpartum Depression Symptoms by Day 7 in Phase 2 RECONNECT<\/strong><\/a><\/p>\n<p class=\"pb-2\">RE104 significantly reduced depressive symptoms by day 7 in patients with postpartum depression, meeting the phase 2 RECONNECT trial\u2019s primary endpoint.<\/p>\n<p class=\"pb-2\">5. <a target=\"_blank\" href=\"https:\/\/www.hcplive.com\/view\/dyslipidemia-other-metabolic-syndrome-factors-may-raise-parkinson-s-disease-risk\" rel=\"nofollow noopener\"><strong>Dyslipidemia, Other Metabolic Syndrome Factors May Raise Parkinson\u2019s Disease Risk<\/strong><\/a><\/p>\n<p class=\"pb-2\">People with metabolic syndrome had about a 40% higher risk of developing Parkinson\u2019s disease compared with those without the condition.<\/p>\n","protected":false},"excerpt":{"rendered":"Welcome to HCPLive&#8217;s 5 Stories in Under 5\u2014your quick, must-know recap of the top 5 healthcare stories from&hellip;\n","protected":false},"author":2,"featured_media":21078,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[78],"tags":[2904,2908,2901,2906,2675,686,718,18,2909,2898,1910,135,474,2911,19,2913,2902,1911,2810,17,693,96,5,2907,2900,2899,1944,2903,171,2905,2912,172,2910,133,2897],"class_list":["post-21077","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-allergy","tag-cardiology","tag-clinicians","tag-dermatology","tag-diabetes","tag-doctors","tag-drugs","tag-eire","tag-endocrinology","tag-fda","tag-gastroenterology","tag-health","tag-healthcare","tag-hematology","tag-ie","tag-infectious-disease","tag-insight","tag-internal-medicine","tag-interviews","tag-ireland","tag-medical","tag-medicine","tag-news","tag-ophthalmology","tag-pharmaceuticals","tag-pipeline","tag-primary-care","tag-providers","tag-psychiatry","tag-pulmonology","tag-rare-disease","tag-research","tag-rheumatology","tag-science","tag-treatments"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/21077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=21077"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/21077\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/21078"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=21077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=21077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=21077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}